Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn, Carla S. Milagre, Steven R. Whittaker et al. · Cell · 2010
We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling. This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS. Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice. Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression. They highlight the importance of understanding pathway signaling in clinical practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.
Cited by 1,465 works. doi:10.1016/j.cell.2009.12.040 Open-access PDF
Authors
- Sonja J. Heidorn
- Carla S. Milagre
- Steven R. Whittaker
- Arnaud Nourry
- Ion Niculescu‐Duvaz
- Nathalie S. Dhomen
- Jahan Hussain
- Jorge Sergio Reis-Filho
- Caroline J. Springer
- Catrin A. Pritchard
- Richard Marais
References
- Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
- Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
- Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
- Melanoma biology and new targeted therapy
- Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation